Suven Life Sciences Limited
Quant Mutual Fund has dropped from Suven Life Sciences Limited's disclosed shareholder list after previously holding 1.78 percent, indicating either a complete exit or a reduction of its stake to below the 1 percent reporting requirement.
A clinical-stage biopharmaceutical company engaged in the acquisition, development, and commercialization of novel therapeutics for treating neurodegenerative disorders. Suven Life Sciences operates across research, analytics, and technology platforms to advance its pipeline of investigational drugs targeting diseases affecting the nervous system. The company focuses on bringing innovative treatment solutions to patients suffering from neurological conditions through rigorous clinical development processes.
Built a quantitative, data-driven investment philosophy in an industry dominated by discretionary stock pickers. Manages over Rs 1.2 lakh crore. Founded by Sanjeev Sharma, Quant MF uses VLRT (Valuation, Liquidity, Risk, and Time) framework to run high-turnover, tactically active portfolios. Grew from obscurity to one of India's top-15 AMCs in under five years, attracting both retail capital and scrutiny for its aggressive churn.